{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"4","value":"3.2"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"3.5","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Defined as the time from the first day of treatment until the date PD(progressive disease) or death is first reported. Patients who died without a reported prior progression was considered to have progressed on the day of their death. Patients who did not progress was censored at the day of their last tumor assessment. According to RECIST, progressive disease(PD) is defined as at least a 20% increase in the sum of the longest diameter of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Carcinoma"},{"description":"Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Carcinosarcoma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Month"}